Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | ADA | P00813 | 11/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410921 | 0.78 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6010326 | 0.78 | ADORA2A (0.44) | ADORA2AADORA1 | |
| SCHEMBL6010032 | 0.73 | ADORA2A (0.37) | ADORA2AADORA1 | |
| SCHEMBL6010413 | 0.68 | ADORA2A (0.39) | ADORA2AADORA3ADORA1ADORA2BCSNK1A1 | |
| SCHEMBL6010331 | 0.66 | ADORA2A (0.45) | ADORA2A | |
| SCHEMBL6010317 | 0.66 | ADORA2A (0.43) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL5651588 | 0.64 | ADORA2A (0.56) | ADORA2AADORA1 | |
| SCHEMBL6009990 | 0.63 | ADORA2A (0.41) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL5656150 | 0.63 | ADORA2A (0.57) | ADORA2AADORA1 | |
| SCHEMBL6010043 | 0.62 | ADORA2A (0.36) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.